RVX-297

Overview

RVX-297 is a potent, orally active BET bromodomain inhibitor with selectivity for BD2 . RVX-297 shows IC 50 s of 0.08, 0.05, and 0.02 μM for BRD2(BD2), BRD3(BD2), and BRD4(BD2), respectively. RVX-297 suppresses inflammatory gene expression in multiple immune cell types. RVX-297 is effective in acute inflammation and autoimmunity models.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Epigenetic Reader Domain

Product Information

• Catalog No.: HY-114504
• CAS No.: 1044871-04-6
• Molecular Formula: C24H29N3O4
• Molecular Weight: 423.50
• Purity: 95.00%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.91 mM); Clear solution
• Availability: In-stock

Source

Original product source